Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

Help for family caregivers is urgently needed in the U.S., as the current situation is untenable, writes columnist.

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...

MaaT033, an experimental oral therapy for improving the gut microbiome — the collection of microbes, including bacteria, in the human gut — was deemed safe and well tolerated in people with ...